Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates.

Kågedal M, Samineni D, Gillespie WR, Lu D, Fine BM, Girish S, Li C, Jin JY.

CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):606-615. doi: 10.1002/psp4.12442. Epub 2019 Jul 10.

2.

Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA.

Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31.

PMID:
31117485
3.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
4.

Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.

Kågedal M, Gibiansky L, Xu J, Wang X, Samineni D, Chen SC, Lu D, Agarwal P, Wang B, Saad O, Koppada N, Fine BM, Jin JY, Girish S, Li C.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):537-548. doi: 10.1007/s10928-017-9544-y. Epub 2017 Sep 16.

PMID:
28918591
5.

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.

Stagg NJ, Shen BQ, Brunstein F, Li C, Kamath AV, Zhong F, Schutten M, Fine BM.

Regul Toxicol Pharmacol. 2016 Dec;82:1-13. doi: 10.1016/j.yrtph.2016.10.012. Epub 2016 Oct 20. Review.

PMID:
27773754
6.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG.

Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20.

7.

Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, Hicks R, Wood K, Amler L, Fine BM, Loecke D, Pirzkall A.

Oncologist. 2014 Feb;19(2):175-6. doi: 10.1634/theoncologist.2013-0026. Epub 2014 Jan 23.

8.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

9.

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.

Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.

Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1.

10.

Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.

Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, Scott AM, Macfarlane D, Fine BM, Hicks RJ; OSI3926g Study Team.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):642-50. doi: 10.1007/s00259-010-1665-0. Epub 2011 Jan 5.

PMID:
21207024
11.

Molecular biomarker analyses using circulating tumor cells.

Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR.

PLoS One. 2010 Sep 8;5(9):e12517. doi: 10.1371/journal.pone.0012517.

12.

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

Fine BM, Amler L.

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18. No abstract available.

PMID:
19295504
13.

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.

Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S.

Cancer Res. 2005 May 15;65(10):4059-66.

14.

A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.

Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM.

Cancer Res. 2005 Jan 1;65(1):291-9.

15.

Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.

Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A, Flohr T, Schäfer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M.

Blood. 2005 Jan 15;105(2):821-6. Epub 2004 Sep 23.

PMID:
15388585
16.

Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia.

Fine BM, Stanulla M, Schrappe M, Ho M, Viehmann S, Harbott J, Boxer LM.

Blood. 2004 Feb 1;103(3):1043-9. Epub 2003 Oct 2.

PMID:
14525776
17.

Dynamic critical phenomena in aqueous protein solutions.

Fine BM, Pande J, Lomakin A, Ogun OO, Benedek GB.

Phys Rev Lett. 1995 Jan 2;74(1):198-201. No abstract available.

PMID:
10057733

Supplemental Content

Support Center